日报更新时间：
周报更新时间：01-23 11:54
今开价：
最高价：
成交量：
昨收价：
最低价：
最新价：
中文名称：癌症遗传学
英文名称：Cancer Genetics
简介：Cancer Genetics, Inc.于1999年4月8日在美国特拉华州注册成立，并在新泽西州的卢瑟福设有办事处和实验室
电话：1-201-5289200
癌症遗传学公司的测试使医生能够通过提供基因组信息来诊断，监测和告知癌症治疗，从而个性化每个患者的临床管理；并使参与肿瘤学和免疫肿瘤学试验的生物技术和制药公司能够通过提供影响受试者对治疗反应的基因组因素的信息来选择候选人群并减少药物不良反应。 Cancer Genetics公司的生物制药服务通过一系列基于分子和生物标记的测试服务，定制化验开发和试验设计咨询，为公司提供定制的患者分层和治疗选择解决方案。 Cancer Genetics临床服务提供有关癌症的诊断，预后和预测治疗结果的信息，以指导患者管理。 Cancer Genetics的发现服务为公司和研究人员提供工具和测试方法，以识别和开发用于疾病诊断和治疗的新化合物和基于分子的生物标记物。癌症遗传学公司为医院，癌症中心，诊所，学术机构和政府资助的研究机构以及进行临床试验的制药和生物技术公司提供服务。癌症遗传学公司与肿瘤中心和社区医院合作开发其专有的诊断测试；并与Cellaria合作开发精密医疗工具和平台技术，以支持新的癌症治疗方法的开发。
| 交易日期 | 交易人 | 职位 | 类型 | 交易份额 | 价格 |
|---|---|---|---|---|---|
| 2019-01-30 | Cannon (Edmund) | Director | Buy | 43479 | 0.23 |
| 2019-01-30 | Roberts (John A) | Chief Executive Officer | Buy | 185436 | 0.23 |
| 2019-01-30 | Miles (Michael Glenn) | Chief Financial Officer | Buy | 150000 | 0.23 |
| 2019-01-30 | Pappajohn (John G) | Director | Buy | 1000000 | 0.23 |
| 2019-01-13 | Roberts (John A) | Chief Executive Officer | Buy | 100000 | 0.23 |
| 2019-01-13 | Harris Geoffrey E | Director | Buy | 100000 | 0.23 |
| 2019-01-13 | Pappajohn (John G) | Director | Buy | 1000000 | 0.23 |
| 2017-12-14 | Roberts (John A) | Chief Operating Officer | Buy | 12200 | 2.00 |
| 2017-12-07 | Pappajohn (John G) | Director and Beneficial Owner | Buy | 150000 | 1.86 |
| 2017-09-27 | McLeod (Howard) | Director | Buy | 2500 | -- |
| 2017-09-27 | Pappajohn (John G) | Director and Beneficial Owner | Buy | 2500 | -- |
| 2017-09-27 | Prendergast (Franklyn G) | Director | Buy | 2500 | -- |
| 2017-09-27 | Harris Geoffrey E | Director | Buy | 2500 | -- |
| 2017-09-27 | Chaganti (Raju S K) | Director | Buy | 2500 | -- |
| 2017-09-27 | Cannon (Edmund) | Director | Buy | 2500 | -- |
| 2017-09-27 | Welsh Michael J | Director | Buy | 2500 | -- |
| 2017-08-17 | Pappajohn (John G) | Director and Beneficial Owner | Buy | 20000 | 3.28 |
| 2017-08-16 | Pappajohn (John G) | Director and Beneficial Owner | Buy | 66185 | 3.24 |
| 机构持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| Morgan Stanley Smith Barney LLC | 12542 | 0.02% | -1250 | -9.06% | 2019-03-31 |
| Diker Management LLC | 64365 | 0.11% | -- | -- | 2019-03-31 |
| Fairbanks Capital Management, Inc. | 82900 | 0.14% | -- | -- | 2019-03-31 |
| Vanguard Group Inc | 194041 | 0.34% | 14690 | 8.19% | 2019-03-31 |
| Virtu Financial LLC | 201080 | 0.35% | 201080 | -- | 2019-03-31 |
| Fidelity Management & Research Company | 217946 | 0.38% | -- | -- | 2019-07-31 |
| Geode Capital Management, LLC | 221803 | 0.38% | -221803 | -50.00% | 2019-03-31 |
| Renaissance Technologies Corp | 2007229 | 3.47% | 1098515 | 120.89% | 2019-03-31 |
| Perkins Capital Management Inc | 3136528 | 5.43% | 2718278 | 649.92% | 2019-03-31 |
| Granahan Investment Management Inc | 60501 | 0.10% | -2800 | -4.42% | 2019-07-31 |
| Satuit Capital Management, LLC | 50000 | 0.09% | -- | -- | 2019-07-31 |
| Northern Trust Investments Inc | 42249 | 0.07% | 699 | 1.68% | 2019-07-31 |
| Morgan Stanley - Brokerage Accounts | 12542 | 0.02% | -1250 | -9.06% | 2019-03-31 |
| Bahl & Gaynor Inc. | 20000 | 0.03% | 10000 | 100.00% | 2019-03-31 |
| Ladenburg Thalmann FI Services Inc | 21794 | 0.04% | 4294 | 24.54% | 2019-03-31 |
| Wedbush Morgan Securities Inc | 24022 | 0.04% | -14510 | -37.66% | 2019-03-31 |
| Northern Trust Investments N A | 32576 | 0.06% | -- | -- | 2019-03-31 |
| Northern Trust Corp | 32576 | 0.06% | -- | -- | 2019-03-31 |
| Royal Bank of Canada | 34000 | 0.06% | 34000 | -- | 2019-03-31 |
| First Premier Bank | 36725 | 0.06% | 36725 | -- | 2019-03-31 |
| Granahan Investment Management Inc.. | 272818 | 0.47% | -5442 | -1.96% | 2018-12-31 |
| Panagora Asset Management Inc | 37319 | 0.06% | -706 | -1.86% | 2018-12-31 |
| BlackRock Asset Management Canada Ltd | 27954 | 0.05% | 304 | 1.10% | 2019-05-31 |
| TWO SIGMA SECURITIES, LLC | 19265 | 0.03% | -4176 | -17.81% | 2018-12-31 |
| Sunrise Partners LLC | 33400 | 0.06% | 33400 | -- | 2018-12-31 |
| Susquehanna Financial Group, LLLP | 27592 | 0.05% | 27592 | -- | 2018-12-31 |
| Susquehanna International Group, LLP | 27592 | 0.05% | 27592 | -- | 2018-12-31 |
| UBS Group AG | 19242 | 0.03% | 15358 | 395.42% | 2018-12-31 |
| Citadel Advisors Llc | 33165 | 0.06% | 33165 | -- | 2018-09-30 |
| Vassalluzzo Scott J | 23175 | 0.06% | 23175 | -- | 2018-09-30 |
| Stonepine Capital Management Llc | 614411 | 2.21% | -777196 | -55.85% | 2018-09-30 |
| Seacrest Wealth Management, LLC | 11000 | 0.04% | 5000 | 83.33% | 2018-06-30 |
| Dimensional Fund Advisors LP | 11966 | 0.04% | -2741 | -18.64% | 2018-11-30 |
| Vanguard Investments Australia Ltd | 14502 | 0.05% | -- | -- | 2018-11-30 |
| Jacobs Levy Equity Management, Inc. | 16489 | 0.06% | -- | -- | 2018-03-31 |
| Dimensional Fund Advisors, Inc. | 19866 | 0.07% | 19866 | -- | 2018-03-31 |
| Spark Investment Management LLC | 11600 | 0.04% | 11600 | -- | 2018-03-31 |
| Court Place Advisors LLC | 10000 | 0.04% | -- | -- | 2018-06-30 |
| Credit Suisse First Boston (CSFB) | 10090 | 0.04% | 10090 | -- | 2018-06-30 |
| Mellon Capital Management Corporation | 7110 | 0.03% | 1628 | 29.70% | 2018-06-30 |
| Ladenburg Thalmann Asset Management Inc | 4500 | 0.03% | -- | -- | 2018-06-30 |
| UBS Securities LLC | 8476 | 0.03% | -52378 | -86.07% | 2018-06-30 |
| Bankinter Gesti¨?n de Activos SGIIC | 3003 | 0.01% | 2 | 0.07% | 2017-12-31 |
| Guggenheim Funds Investment Advisors LLC | 6547 | 0.03% | -- | -- | 2018-09-14 |
| BlackRock Inc | 5433 | 0.02% | -39487 | -87.91% | 2018-06-30 |
| Wells Fargo Advisors, LLC | 1800 | 0.01% | -8000 | -81.63% | 2018-06-30 |
| Wells Fargo Bank NA | 7000 | 0.03% | 4000 | 133.33% | 2018-03-31 |
| HRT FINANCIAL LLC | 26211 | 0.09% | 3012 | 12.98% | 2018-03-31 |
| Sabby Management LLC | 942491 | 4.98% | -139009 | -12.85% | 2016-12-31 |
| BlackRock Fund Advisors | 42036 | 0.19% | 2 | -- | 2018-03-22 |
| Thompson Davis & Co Inc | 46975 | 0.19% | -64325 | -57.79% | 2017-09-30 |
| Pnc Bank, National Association | 6000 | 0.02% | -- | -- | 2017-09-30 |
| SWK Holdings Corp | 736076 | 3.90% | -- | -- | 2016-11-14 |
| BMO Asset Management Inc | 12106 | 0.05% | -2508 | -17.16% | 2017-09-30 |
| Eagle Global Advisors, LLC | 22170 | 0.11% | 22170 | -- | 2017-06-30 |
| Empery Asset Management, LP | 833300 | 6.10% | -- | -- | 2015-12-31 |
| Frigate Ventures LP | 271722 | 1.44% | 271722 | -- | 2016-09-30 |
| Tocqueville Asset Management L.P. | 23800 | 0.13% | -23800 | -50.00% | 2016-09-30 |
| Brown Investment Advisory Incorporated | 16000 | 0.08% | -2000 | -11.11% | 2016-09-30 |
| Sterneck Capital Management LLC | 14370 | 0.08% | -380 | -2.58% | 2016-09-30 |
| Merrill Lynch & Co Inc | 10191 | 0.05% | 9647 | 1773.35% | 2016-09-30 |
| Next Financial Group Inc | 7500 | 0.04% | 7500 | -- | 2016-09-30 |
| Bank of Montreal | 648861 | 3.00% | 5054627 | 0.10% | 1999-11-30 |
| John Pappajohn | 1514289 | 3.00% | 11796311 | 0.20% | 1999-11-30 |
| 共同基金持股 | |||||
|---|---|---|---|---|---|
| 持有者 | 持有份额 | 持股比例 | 份额变化 | 变化率 | 报告日期 |
| iShares Core S&P US Total Mkt ETF CADH | -- | -- | -16 | -100.00% | 2019-07-31 |
| Vanguard Extended Market Index Fund | 194041 | 0.34% | -- | -- | 2019-06-30 |
| Granahan US Small Cap Discoveries Fund | 60501 | 0.10% | -2800 | -4.42% | 2018-12-31 |
| Satuit Capital US Emerging Companies Fd | 50000 | 0.09% | -- | -- | 2018-11-30 |
| NT Ext Equity Market Index Fund - L | 17068 | 0.03% | -- | -- | 2019-06-30 |
| NT Extended Equity Market Idx Fund - NL | 13428 | 0.02% | -- | -- | 2019-06-30 |
| NT Ext Equity Mkt Fd - DC - NL | 9608 | 0.02% | 699 | 7.85% | 2019-06-30 |
| iShares Core S&P Total US Stock Mkt ETF | 7206 | 0.01% | -- | -- | 2019-07-30 |
| Fidelity | 7133 | 0.01% | -- | -- | 2019-06-30 |
| NT US Market Cap Index Fund - Lending | 2080 | -- | -- | -- | 2019-06-30 |
| NT US Market Cap Index Fund - NL | 65 | -- | -- | -- | 2018-12-31 |
| Invesco Wilshire Micro-Cap ETF | -- | -- | -4877 | -100.00% | 2019-02-22 |
| BNYM Mellon SL Mkt Completion Fd | -- | -- | -1540 | -100.00% | 2019-06-30 |
| BNYM Mellon NSL Mkt Completion Fd Instl | -- | -- | -5248 | -100.00% | 2019-06-30 |
| iShares Core MSCI AllCntry Wld exCan ETF | -- | -- | -7 | -100.00% | 2019-07-25 |
| Vanguard Balanced Index Fund | -- | -- | -23618 | -100.00% | 2018-12-31 |
| Vanguard Instl Total Stock Market Idx Fd | -- | -- | -31225 | -100.00% | 2018-12-31 |
| iShares Core Growth ETF Portfolio | -- | -- | -31 | -100.00% | 2019-07-25 |
| NT Ext Equity Mkt Idx Fd - DC - NL | 9608 | 0.02% | 699 | 7.85% | 2019-06-30 |
| Kaldi Capital SICAV | 3001 | 0.01% | 2 | 0.07% | 2018-09-30 |
| iShares Core S&P US Total Market ETF | 225 | -- | 12 | 5.63% | 2019-06-28 |
| iShares Core Balanced ETF Portfolio | 17 | -- | 1 | 6.25% | 2019-06-28 |
| Vanguard Total Stock Market Index Fund | -- | -- | -357272 | -100.00% | 2018-12-31 |
| BNYM Mellon NSL Market Completion Fund | 5248 | 0.01% | 5146 | 5045.10% | 2019-03-31 |
| BNYM Mellon SL Market Completion Fund | 1540 | -- | -3880 | -71.59% | 2019-03-31 |
| The Vanguard Total Stock Market Index | -- | -- | -3400 | -100.00% | 2018-06-30 |
| 1290 VT Micro Cap Portfolio | -- | -- | -2676 | -100.00% | 2018-06-30 |
| BNY Mellon Market Completion Fund | 102 | -- | -1630 | -94.11% | 2018-12-31 |
| iShares Micro-Cap ETF | 4212 | 0.01% | -41887 | -90.86% | 2018-06-22 |
| DFA Tax-Managed US Targeted Value Port | -- | -- | -2066 | -100.00% | 2018-04-30 |
| DFA US Micro Cap Portfolio | -- | -- | -1400 | -100.00% | 2018-04-30 |
| DFA US Small Cap Portfolio | -- | -- | -8500 | -100.00% | 2018-04-30 |
| Vanguard Extended Market Idx Inv | 179351 | 0.65% | -- | -- | 2018-07-31 |
| Vanguard Instl Ttl Stk Mkt Idx InstlPls | 31225 | 0.11% | -- | -- | 2018-07-31 |
| Vanguard Balanced Index Inv | 17202 | 0.06% | -- | -- | 2018-07-31 |
| Vanguard Total Stock Mkt Idx | 14502 | 0.05% | -- | -- | 2018-07-31 |
| Fidelity Spartan | 9725 | 0.04% | -- | -- | 2018-07-31 |
| Wilshire Micro-Cap ETF | 6547 | 0.03% | -- | -- | 2018-09-14 |
| iShares Core S&P Total US Stock Mkt | 5543 | 0.02% | -- | -- | 2018-09-12 |
| BNY Mellon EB DL Mkt Completion | 5379 | 0.02% | -- | -- | 2018-06-30 |
| BNY Mellon Market Completion Fund UC1 | 1731 | 0.01% | 1628 | 1580.58% | 2018-03-31 |
| Satuit Capital US Emerging Companies A | 50000 | -- | -- | -- | 2018-07-31 |
| AXA/Lord Abbett Micro Cap K | 2676 | 0.01% | -- | -- | 2018-05-31 |
| iShares Micro-Cap | 46099 | 0.17% | -- | -- | 2018-06-21 |
| DFA US Small Cap I | 8500 | 0.03% | -- | -- | 2018-03-31 |
| DFA Tax-Managed US Targeted Value | 2066 | 0.01% | -2741 | -57.02% | 2018-03-31 |
| DFA US Micro Cap I | 1400 | 0.01% | -- | -- | 2018-03-31 |
| Tocqueville Opportunity | 15000 | 0.08% | -8800 | -36.97% | 2016-12-31 |
| AllianzGI Ultra Micro Cap Fund | 58548 | 0.60% | -- | -- | 2015-09-30 |
| Balter Long/Short Equity Fund | 49542 | 0.50% | 6520 | 15.20% | 2015-07-31 |
| Allianz US Ultra Micro Cap | 30303 | 0.30% | -- | -- | 2015-08-31 |
| CF Richmond Core Fd | 30000 | 0.30% | 18000 | 150.00% | 2015-07-31 |
| Fidelity Spartan® Extended Mkt Indx Fd | 27876 | 0.30% | -- | -- | 2015-09-30 |
| Royce Value Trust | 17400 | 0.20% | -39500 | -69.40% | 2015-09-30 |
| Cornerstone Advisors Glbl Public Eq Fund | 17374 | 0.20% | -- | -- | 2015-09-30 |
| Jacob Micro Cap Growth Fund | 14954 | 0.20% | -5000 | -25.10% | 2015-09-30 |
| Westcore Micro Cap Opportunity Fund | 14141 | 0.10% | -- | -- | 2015-10-31 |
| Fidelity Spartan® Total Market Idx Fund | 9725 | 0.10% | -- | -- | 2015-09-30 |
| Turner Medical Sciences Long/Short | 92730 | 0.90% | -- | -- | 2015-09-30 |
| John Pappajohn | Mr. John Pappajohn is an Independent Director at MYnd Analytics, Inc., a Non-Executive Chairman at Cancer Genetics, Inc., a President, Chief Executive Officer & Director at Zeta Acquisition Corp. I, a President, Chief Executive Officer & Director at Zeta Acquisition Corp. II, a Chairman at American CareSource Holdings, Inc., a President & Owner at Equity Dynamics, Inc., a President & Owner at Pappajohn Capital Resources and a Chairman at e-Marine Co. Ltd. He is on the Board of Directors at MYnd Analytics, Inc., Zeta Acquisition Corp. I, Zeta Acquisition Corp. II, Advanced Analytical Technologies, Inc., Business Committee for the Arts, Inc. and State University of Iowa Foundation. Mr. Pappajohn was previously employed as a President, Chief Executive Officer & Director by Zeta Acquisition Corp. III, a Chairman by PharmAthene, Inc., a Chairman & Secretary by Healthcare Acquisition Corp., an Independent Director by Conmed Healthcare Management, Inc., a Founder by Caremark Rx, Inc., a Founder by Accredo Health Group, Inc., a Founder by Quantum Health Resources & Associates, and a Founder by Radiologix, Inc. He also served on the board at SpectraScience, Inc., CareGuide, Inc., PACE Health Management Systems, Inc., MC Informatics, Inc., Allion Healthcare, Inc. and Patient Infosystems, Inc. He received his undergraduate degree from the University of Iowa. |
|---|---|
| Edmund M. Cannon | Edmund M. Cannon founded Clinical Research Center of Cape Cod, Inc. and Alletess, Inc. Presently, he occupies the position of President of Clinical Research Center of Cape Cod, Inc. Mr. Cannon is also on the board of Cancer Genetics, Inc. In the past Mr. Cannon held the position of Vice President of Alletess, Inc. and Principal at Franey Medical Labs. Mr. Cannon received a graduate degree from Providence College and an undergraduate degree from Boston College. |
| Geoffrey Eric Harris | Geoffrey Eric Harris is Managing Partner & Portfolio Manager at C7 Advisors LLC and on the board of 7 other companies. In the past he occupied the position of Principal at Sirios Capital Management LP, Co-Head-Healthcare Investment Banking at Cantor Fitzgerald & Co., Vice President at Tucker Anthony Cleary Gull, Managing Director at UBS Asset Management (US), Inc., Portfolio Manager at CoreCommodity Management LLC, Managing Director at Broadpoint.Gleacher Asset Management, Managing Director at Gleacher & Co. Securities, Inc. and Managing Director at Broadpoint.Gleacher Securities. Mr. Harris received an undergraduate degree from Oberlin College and a graduate degree from MIT Sloan School of Management. |
| Franklyn G. Prendergast | Dr. Franklyn G. Prendergast is an Independent Director at Cancer Genetics, Inc., a Chairman at Infectious Disease Research Institute, a Professor at Mayo Clinic College of Medicine, an Independent Director at NeuBase Therapeutics, Inc., a Member at American Cancer Society, Inc., a Member at American Chemical Society, a Member at American Society for Biochemistry & Molecular Biology, Inc., a Member at Sigma XI, a Member at The Biophysical Society and a Professor at Mayo Foundation for Medical Education & Research. He is on the Board of Directors at Medibio Ltd., Cancer Genetics, Inc., Acelerate, Inc., DemeRx, Inc., On Target Laboratories LLC, Perimeter Medical Imaging, Inc., Predictive Health Technologies, Inc. and NeuBase Therapeutics, Inc. Dr. Prendergast was previously employed as an Independent Director by Eli Lilly & Co., a Trustee by The Mayo Clinic (Old), a Member-Governors Board by Mayo Clinic Rochester, a Chairman-Biochemistry & Molecular Biology by Mayo Foundation for Medical Education & Research, a Member by American Association for the Advancement of Science, a Professor by Mayo Medical School, a Member by Molecular Biology Resources, Inc., a Principal by National Academy of Sciences, a Member-Scientific Advisory Board by National Cancer Institute, and a Principal by National Institute of Health Policy. He also served on the board at Neubase Therapeutics, Inc. /Old/, Mayo Clinic Cancer Center, Ativa Medical Corp., GMP Cos., Inc., Liquid Bioscience, Inc. and Translational Genomics Research Institute. He received his undergraduate degree from the University of Oxford, an undergraduate degree from The University of the West Indies, a graduate degree from the University of Oxford and a doctorate degree from the University of Minnesota. |
| Marie-Agnes Patrone-Michellod | Marie-Agnes Patrone-Michellod occupies the position of Manager-Regulatory Affairs & Marketing at Cancer Genetics, Inc. |
| John A. Roberts | Presently, John A. Roberts is President & Chief Executive Officer at Cancer Genetics, Inc. He is also Chairman-Elect at Drug Information Association. In the past he was CFO & SVP-Corporate Development at HealthOnLine, Principal at Stanley Black & Decker, Inc. and Chief Financial Officer at Infologix, Inc. (a subsidiary of Stanley Black & Decker, Inc.), Chief Financial Officer & Secretary of Daou Systems, Inc., Chief Financial Officer & Secretary of Clarient, Inc., Chief Financial & Administrative Officer at AdvantEdge Healthcare Solutions, Inc. and Vice President-Business Development of MEDecision, Inc. He received an undergraduate degree and an MBA from the University of Maine. |
| Raju S. K. Chaganti | Founder of Cancer Genetics, Inc., Raju S. K. Chaganti is on the board of Cancer Genetics, Inc. (former Chairman) and Cancer Genetics (India) Pvt Ltd. and Professor at Gerstner Sloan Kettering Graduate School of Biomedical Science. In the past he held the position of Principal at Cell Biology & Physiology and Chief Executive Officer at Memorial Sloan-Kettering Cancer Center. He received a doctorate from Harvard University. |
| John A. Roberts | Presently, John A. Roberts is President & Chief Executive Officer at Cancer Genetics, Inc. He is also Chairman-Elect at Drug Information Association. In the past he was CFO & SVP-Corporate Development at HealthOnLine, Principal at Stanley Black & Decker, Inc. and Chief Financial Officer at Infologix, Inc. (a subsidiary of Stanley Black & Decker, Inc.), Chief Financial Officer & Secretary of Daou Systems, Inc., Chief Financial Officer & Secretary of Clarient, Inc., Chief Financial & Administrative Officer at AdvantEdge Healthcare Solutions, Inc. and Vice President-Business Development of MEDecision, Inc. He received an undergraduate degree and an MBA from the University of Maine. |
| Edmund M. Cannon | Edmund M. Cannon founded Clinical Research Center of Cape Cod, Inc. and Alletess, Inc. Presently, he occupies the position of President of Clinical Research Center of Cape Cod, Inc. Mr. Cannon is also on the board of Cancer Genetics, Inc. In the past Mr. Cannon held the position of Vice President of Alletess, Inc. and Principal at Franey Medical Labs. Mr. Cannon received a graduate degree from Providence College and an undergraduate degree from Boston College. |
| Ralf Brandt | Dr. Ralf Brandt is a President-Discovery & Early Development at Cancer Genetics, Inc. and a Member-Scientific Advisory Board at Receptors, Inc. Dr. Brandt was previously employed as a President-Discovery & Early Development by vivoPharm Pty Ltd. and a Principal by National Cancer Institute. He received his undergraduate degree from Martin-Luther-Universit�0�1¤t Halle-Wittenberg and a doctorate degree from Martin-Luther-Universit�0�1¤t Halle-Wittenberg. |
| Edmund M. Cannon | Edmund M. Cannon founded Clinical Research Center of Cape Cod, Inc. and Alletess, Inc. Presently, he occupies the position of President of Clinical Research Center of Cape Cod, Inc. Mr. Cannon is also on the board of Cancer Genetics, Inc. In the past Mr. Cannon held the position of Vice President of Alletess, Inc. and Principal at Franey Medical Labs. Mr. Cannon received a graduate degree from Providence College and an undergraduate degree from Boston College. |
| Pal Singh-Kahlon | Pal Singh-Kahlon is Member of American Society of Human Genetics, Member of American College of Medical Genetics & Genomics, Member of Association for Molecular Pathology and Cytogenetics Director at Cancer Genetics, Inc. |
| Franklyn G. Prendergast | Dr. Franklyn G. Prendergast is an Independent Director at Cancer Genetics, Inc., a Chairman at Infectious Disease Research Institute, a Professor at Mayo Clinic College of Medicine, an Independent Director at NeuBase Therapeutics, Inc., a Member at American Cancer Society, Inc., a Member at American Chemical Society, a Member at American Society for Biochemistry & Molecular Biology, Inc., a Member at Sigma XI, a Member at The Biophysical Society and a Professor at Mayo Foundation for Medical Education & Research. He is on the Board of Directors at Medibio Ltd., Cancer Genetics, Inc., Acelerate, Inc., DemeRx, Inc., On Target Laboratories LLC, Perimeter Medical Imaging, Inc., Predictive Health Technologies, Inc. and NeuBase Therapeutics, Inc. Dr. Prendergast was previously employed as an Independent Director by Eli Lilly & Co., a Trustee by The Mayo Clinic (Old), a Member-Governors Board by Mayo Clinic Rochester, a Chairman-Biochemistry & Molecular Biology by Mayo Foundation for Medical Education & Research, a Member by American Association for the Advancement of Science, a Professor by Mayo Medical School, a Member by Molecular Biology Resources, Inc., a Principal by National Academy of Sciences, a Member-Scientific Advisory Board by National Cancer Institute, and a Principal by National Institute of Health Policy. He also served on the board at Neubase Therapeutics, Inc. /Old/, Mayo Clinic Cancer Center, Ativa Medical Corp., GMP Cos., Inc., Liquid Bioscience, Inc. and Translational Genomics Research Institute. He received his undergraduate degree from the University of Oxford, an undergraduate degree from The University of the West Indies, a graduate degree from the University of Oxford and a doctorate degree from the University of Minnesota. |
| Howard McLeod | Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy. |
| Howard McLeod | Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy. |
| Howard McLeod | Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy. |
| Howard McLeod | Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy. |
| Howard McLeod | Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy. |
| John A. Roberts | Presently, John A. Roberts is President & Chief Executive Officer at Cancer Genetics, Inc. He is also Chairman-Elect at Drug Information Association. In the past he was CFO & SVP-Corporate Development at HealthOnLine, Principal at Stanley Black & Decker, Inc. and Chief Financial Officer at Infologix, Inc. (a subsidiary of Stanley Black & Decker, Inc.), Chief Financial Officer & Secretary of Daou Systems, Inc., Chief Financial Officer & Secretary of Clarient, Inc., Chief Financial & Administrative Officer at AdvantEdge Healthcare Solutions, Inc. and Vice President-Business Development of MEDecision, Inc. He received an undergraduate degree and an MBA from the University of Maine. |
| John A. Roberts | Presently, John A. Roberts is President & Chief Executive Officer at Cancer Genetics, Inc. He is also Chairman-Elect at Drug Information Association. In the past he was CFO & SVP-Corporate Development at HealthOnLine, Principal at Stanley Black & Decker, Inc. and Chief Financial Officer at Infologix, Inc. (a subsidiary of Stanley Black & Decker, Inc.), Chief Financial Officer & Secretary of Daou Systems, Inc., Chief Financial Officer & Secretary of Clarient, Inc., Chief Financial & Administrative Officer at AdvantEdge Healthcare Solutions, Inc. and Vice President-Business Development of MEDecision, Inc. He received an undergraduate degree and an MBA from the University of Maine. |
| Michael McCartney | Michael McCartney is Chief Commercial Officer at Cancer Genetics, Inc. In his past career he was Chief Operating Officer of SciKon Innovation, Inc. He received an MBA from LaSalle University and an undergraduate degree from Indiana University of Pennsylvania. |
| Ehab Elkhouly | Ehab Elkhouly holds the position of VP-Clinical Affairs & Site Operations at Cancer Genetics, Inc. In the past Dr. Elkhouly occupied the position of Operations Director for Response Genetics, Inc. Dr. Elkhouly received an undergraduate degree from KasrAlAiny School of Medicine and a graduate degree from Paul Merage School of Business. |
| Glenn Miles | Mr. Glenn Miles is a Chief Financial Officer at Cancer Genetics, Inc., a President & Chief Financial Officer at Catalytic Consulting LLC, a Member at American College of Healthcare Executives, a Member at Financial Executives International, a Member at Healthcare Financial Management Association and a Member at The American Institute of Certified Public Accountants. Mr. Miles was previously employed as a Controller-Developed Europe & Latin America by Pfizer Inc. and an Accountant by Grant Thornton LLP. He received his undergraduate degree from The University of Alabama and an MBA from Mercer University. |
| Glenn Miles | Mr. Glenn Miles is a Chief Financial Officer at Cancer Genetics, Inc., a President & Chief Financial Officer at Catalytic Consulting LLC, a Member at American College of Healthcare Executives, a Member at Financial Executives International, a Member at Healthcare Financial Management Association and a Member at The American Institute of Certified Public Accountants. Mr. Miles was previously employed as a Controller-Developed Europe & Latin America by Pfizer Inc. and an Accountant by Grant Thornton LLP. He received his undergraduate degree from The University of Alabama and an MBA from Mercer University. |
| William Finger | William Finger is EVP-Precision Medicine & Biopharma Solutions at Cancer Genetics, Inc. He received a graduate degree from the University of North Carolina at Chapel Hill and an undergraduate degree from The State University of New York. |
abu_quant
扫一扫关注阿布量化
热门推荐
全部评论 4
【疫苗股和血浆类股均普遍下跌】疫苗股Alpha Pro Tech跌超10%，诺瓦瓦克斯跌超9%，Inovio跌约6.0%，Moderna跌约2.3%，辉瑞制药跌约0.7%、其德国合作伙伴BioNTech也跌4.8%，阿斯利康则涨0.4%。血浆股iBio跌约10.6%，Thermogenesis跌约9.0%，Sonnet Biotherapeutics和Cancer Genetics均跌超6.5%，Liminal BioSciences和Cerus至少跌超5.6%。
【疫苗股和血浆类股均普遍下跌】疫苗股Alpha Pro Tech跌超10%，诺瓦瓦克斯跌超9%，Inovio跌约6.0%，Moderna跌约2.3%，辉瑞制药跌约0.7%、其德国合作伙伴BioNTech也跌4.8%，阿斯利康则涨0.4%。血浆股iBio跌约10.6%，Thermogenesis跌约9.0%，Sonnet Biotherapeutics和Cancer Genetics均跌超6.5%，Liminal BioSciences和Cerus至少跌超5.6%。
【血浆类股普跌，卫生专家们用数据否定特朗普用血浆来治疗新冠肺炎的行动】Adma Biologics下跌7.6%，Kamada跌6.7%，Liminal BioSciences跌5.3%，Sonnet Biotherapeutics跌超3.0%，Grifols跌1.7%，Cancer Genetics涨超3.7%，T2 Biosystems涨1.5%，Thermogenesis Holdings涨0.5%。美国国立卫生研究院（NIH）专家组表示，数据未能支持总统特朗普关于用血浆来治疗新冠肺炎病毒的想法，一项研究结果表明，那些接受高含量抗体的人“在为期七天的存活试验中并未出现任何治疗效果”。相比之下，美国食品药品管理局（FDA）此前表示，通过血浆治疗，死亡病例可以锐减35%。
美股多只生物制药概念个股大涨，Cancer Genetics(CGIX.O)涨近150%，iBio(IBIO.O)涨45%，Sonnet BioTherapeutics(SONN.O)涨近50%，ADMA生物(ADMA.O)涨17.3%。日前美国药监局向血浆疗法授予使用紧急授权（EUA），治疗医院收治的新冠肺炎病人。